Vanguard Global Advisers’s Cardlytics CDLX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$4.5K Hold
1,532
– – ﹤0.01% 3603
2026
Q2
$6.88K Hold
1,532
– – ﹤0.01% 3529
2026
Q1
$16.1K Buy
+1,532
New +$14.9K ﹤0.01% 3378

Other funds holding CDLX

Vanguard Global Advisers's CDLX Position: Q3 2026 in Review

Vanguard Global Advisers held its Cardlytics (CDLX) position steady in Q3 2026 at 1,532 shares worth $4.5K. The position accounts for ﹤0.01% of the portfolio, ranked #3603.

Vanguard Global Advisers first reported a position in CDLX in Q1 2026 and has held it in 3 quarters since. The position peaked at $16.1K in Q1 2026. 40 funds tracked by Wall St. Rank hold CDLX as of Q3 2026.

  • Vanguard Global Advisers held 1,532 shares of Cardlytics worth $4.5K as of Q3 2026.
  • Vanguard Global Advisers left its Cardlytics share count unchanged in Q3 2026.
  • Cardlytics made up ﹤0.01% of Vanguard Global Advisers's portfolio in Q3 2026, its #3603 holding.
  • Vanguard Global Advisers first reported a position in Cardlytics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Global Advisers's Cardlytics position peaked at $16.1K in Q1 2026.
  • 40 funds tracked by Wall St. Rank held Cardlytics as of Q3 2026.

Based on Vanguard Global Advisers's 13F filing for Q3 2026, filed 13 Nov 2026.